Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 24, 2026
IONQ and RGTI: Contrasting Paths in Quantum Computing

IONQ and RGTI: Contrasting Paths in Quantum Computing

Key Takeaways

  • IONQ operates a diversified "full-stack" quantum platform spanning computing, networking, and sensing, while RGTI focuses on vertically integrated superconducting quantum computers.
  • IonQ has delivered rapid revenue growth and became the first public quantum company to exceed $100 million in annual revenue; Rigetti's revenue base remains far smaller and more contract-dependent.
  • Rigetti recently secured a substantial federal funding agreement, adding credibility, while IonQ has strengthened its balance sheet and pursued major acquisitions.
  • Both stocks carry elevated valuations, persistent operating losses, and high sensitivity to sector-wide sentiment and government policy news.
  • Relative performance has swung sharply, reflecting how momentum and catalysts, rather than current earnings, tend to drive these names.

Why This Comparison Matters

Quantum computing stocks have become some of the most closely watched — and volatile — names in the technology market, and IONQ and RGTI sit near the center of that conversation. This comparison is relevant for growth-oriented traders and investors who are comfortable with elevated risk and are evaluating two companies taking meaningfully different technical paths toward commercial quantum computing. While both benefit from the same broad sector tailwinds, their business models, revenue profiles, and recent market positioning differ enough to matter. Understanding those contrasts — rather than treating the two as interchangeable — is essential for anyone assessing relative performance and long-term positioning in this emerging industry. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.

IONQ's Position and Recent Momentum

IonQ positions itself as a full-stack quantum platform and "merchant supplier," spanning quantum computing, networking, sensing, and security rather than computing alone. Its trapped-ion approach emphasizes high-fidelity qubits, and the company has reported technical milestones including record two-qubit gate fidelity, which management frames as a durable advantage in error correction. Recent market activity has been shaped by strong top-line momentum. IonQ reported quarterly revenue up more than 400% year over year, pushing full-year revenue past $130 million and making it the first publicly traded quantum company to surpass $100 million in annual revenue under generally accepted accounting principles (GAAP). Growth has been fueled by government and enterprise contracts, international expansion, and cloud-platform adoption. Strategically, IonQ has completed acquisitions to broaden its platform and announced a pending acquisition aimed at strengthening domestic manufacturing. With a cash position measured in the billions, IonQ carries meaningful balance-sheet strength relative to its peers, though operating losses and heavy research spending remain significant considerations for sentiment.

RGTI's Developments and Challenges

Rigetti Computing builds superconducting quantum processors and pursues a vertically integrated model, designing and fabricating its chips in-house. Its roadmap emphasizes chiplet-based scaling and fast gate speeds, and it sells on-premises systems to national laboratories and research centers while also offering cloud access. Rigetti's recent performance reflects a mix of validation and execution pressure. The company reported annual revenue in the single-digit millions, a modest and contract-dependent base that declined from the prior year, alongside substantial operating losses. However, recent weeks have brought notable catalysts: Rigetti signed a roughly $100 million agreement with the U.S. Department of Commerce under the CHIPS Act to accelerate superconducting quantum research and development, with the government taking a minority, non-controlling equity stake. This marked a meaningful credibility signal for the stock. At the same time, insider share sales and uneven execution have kept sentiment mixed, and the share price has been highly volatile, giving back much of a substantial late-2025 rally. From what I see, tracking these catalysts closely helps put the moves in context.

Direct Comparison of the Two

The clearest contrast between the two companies lies in scale and breadth. IonQ's revenue is substantially larger and growing rapidly, and its platform extends beyond computing into networking and sensing, creating multiple potential revenue streams. Rigetti's business is more narrowly concentrated in superconducting hardware, with a smaller but still strategically significant revenue base tied to government and research contracts. Technologically, the two pursue different qubit modalities — trapped-ion for IonQ versus superconducting for Rigetti — which implies different trade-offs in fidelity, gate speed, and scaling economics. On financial positioning, IonQ's multi-billion-dollar cash balance and acquisition pipeline contrast with Rigetti's leaner balance sheet and its reliance on federal funding to reinforce its roadmap. In terms of momentum, both stocks are prone to sharp, sentiment-driven swings tied to sector news, analyst coverage, and government quantum policy. Risk factors overlap considerably: extended timelines to profitability, high valuations relative to sales, and dependence on milestone execution rather than current earnings.

AI Insights on the Pair

Based on observable factors, Tickeron's AI would likely assign a relative edge to IONQ on trend consistency and financial positioning. Its larger revenue base, stronger cash reserves, and broader, multi-segment platform provide a comparatively steadier foundation and a more diversified set of potential catalysts than RGTI, whose story currently leans more heavily on a single recent government award and a smaller commercial base. That said, this is a probabilistic read rather than a definitive call: Rigetti's federal backing and vertically integrated fabrication model could support stronger momentum if execution milestones land. In a sector where sentiment can shift rapidly, the AI framework would favor the name with more durable fundamentals and lower near-term execution risk, while continuing to monitor both for catalyst-driven changes in trend. I’m watching this closely as new data comes in.

Exploring Automated Strategies with Tickeron

In my own research, I often turn to Tickeron’s AI Trading Bots to see how automated systems are approaching these volatile names. The platform hosts hundreds of bots with varying styles, timeframes, and performance statistics, offering a focused way to evaluate quantitative strategies across the quantum-computing space and beyond. Reviewing them has helped me assess positioning without relying solely on manual analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IONQ, RGTI

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


IONQ in +5.01% Uptrend, advancing for three consecutive days on September 23, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IONQ advanced for three days, in 240 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on IONQ as a result. In 64 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for IONQ just turned positive on September 18, 2026. Looking at past instances where IONQ's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.

IONQ moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for IONQ crossed bearishly below the 50-day moving average on August 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

The 50-day moving average for IONQ moved below the 200-day moving average on August 20, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONQ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

IONQ broke above its upper Bollinger Band on September 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IONQ entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. IONQ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.179) is normal, around the industry mean (7.624). P/E Ratio (102.385) is within average values for comparable stocks, (50.493). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (23.984). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (51.020) is also within normal values, averaging (51.774).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Dell Technologies (NYSE:DELL), Arista Networks Inc (NYSE:ANET), Seagate Technology Holdings PLC (NASDAQ:STX), Western Digital Corp (NASDAQ:WDC), HP (NYSE:HPQ), 3D Systems Corp (NYSE:DDD).

Industry description

Computer Processing Hardware industry produces central processing unit, monitor, keyboard, computer data storage devices, and graphics card. Business activity and economic growth are potential drivers of this industry – if more businesses are growing or flourishing, so would their investments in computer equipment. Dell Technologies, Inc, Hewlett Packard Enterprise Co., NCR Corporation are key producers of computer processing hardware.

Market Cap

The average market capitalization across the Computer Processing Hardware Industry is 32.5B. The market cap for tickers in the group ranges from -0.18 to 349.59B. DELL holds the highest valuation in this group at 349.59B. The lowest valued company is HAUP at -0.18.

High and low price notable news

The average weekly price growth across all stocks in the Computer Processing Hardware Industry was 2%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 48%. CAN experienced the highest price growth at 27%, while XTND experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Computer Processing Hardware Industry was -30%. For the same stocks of the Industry, the average monthly volume growth was -24% and the average quarterly volume growth was -16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 67
Price Growth Rating: 55
SMR Rating: 79
Profit Risk Rating: 85
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
IONQ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry ComputerProcessingHardware

Industry
N/A
Address
4505 Campus Drive
Phone
+1 301 298-7997
Employees
1132
Web
https://www.ionq.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.